Steven Cohen's ACAD Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.49 M shares of ACADIA Pharmaceuticals Inc. (ACAD) worth $31.72 M, representing 0.05% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in ACAD, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2024, adding 2.93 M shares. Largest reduction occurred in Q1 2019, reducing 1.86 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's ACADIA Pharmaceuticals (ACAD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ACADIA Pharmaceuticals (ACAD) Trades by Steven Cohen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2014 | +1.08 M | Add 0.00% | 1.08 M | $22.59 |
| Q3 2014 | -157,000 | Reduce 14.51% | 925,000 | $24.76 |
| Q4 2014 | +93,600 | Add 10.12% | 1.02 M | $31.75 |
| Q1 2015 | +1.23 M | Add 120.63% | 2.25 M | $32.59 |
| Q2 2015 | -900,044 | Reduce 40.05% | 1.35 M | $41.88 |
| Q3 2015 | +664,744 | Add 49.34% | 2.01 M | $33.07 |
| Q4 2015 | -1.71 M | Reduce 84.90% | 303,800 | $35.65 |
| Q1 2016 | +1.92 M | Add 631.63% | 2.22 M | $27.96 |
| Q2 2016 | -1.02 M | Reduce 46.03% | 1.2 M | $32.46 |
| Q3 2016 | +871,800 | Add 72.67% | 2.07 M | $31.81 |
| Q4 2016 | -846,500 | Reduce 40.86% | 1.22 M | $28.84 |
| Q1 2017 | +706,200 | Add 57.65% | 1.93 M | $34.38 |
| Q2 2017 | -525,178 | Reduce 27.19% | 1.41 M | $27.89 |
| Q3 2017 | -680,822 | Reduce 48.42% | 725,200 | $37.67 |
| Q4 2017 | +1.67 M | Add 230.41% | 2.4 M | $30.11 |
| Q1 2018 | +1.96 M | Add 81.86% | 4.36 M | $22.47 |
| Q2 2018 | -1.26 M | Reduce 28.98% | 3.09 M | $15.27 |
| Q3 2018 | -1.29 M | Reduce 41.61% | 1.81 M | $20.76 |
| Q4 2018 | +439,600 | Add 24.33% | 2.25 M | $16.17 |
| Q1 2019 | -1.86 M | Reduce 82.57% | 391,528 | $26.85 |
| Q2 2019 | -389,928 | Reduce 99.59% | 1,600 | $26.88 |
| Q3 2019 | -1,600 | Sold Out | 1,600 | $0.00 |
| Q4 2019 | +671,009 | New Buy | 671,009 | $42.78 |
| Q1 2020 | -671,009 | Sold Out | 671,009 | $0.00 |
| Q2 2020 | +198,510 | New Buy | 198,510 | $48.47 |
| Q3 2020 | +379,685 | Add 191.27% | 578,195 | $41.25 |
| Q4 2020 | -411,095 | Reduce 71.10% | 167,100 | $53.46 |
| Q1 2021 | -167,100 | Sold Out | 167,100 | $0.00 |
| Q4 2022 | +1.12 M | New Buy | 1.12 M | $15.92 |
| Q1 2023 | -456,394 | Reduce 40.90% | 659,506 | $18.82 |
| Q2 2023 | +232,420 | Add 35.24% | 891,926 | $23.95 |
| Q3 2023 | -841,283 | Reduce 94.32% | 50,643 | $20.84 |
| Q4 2023 | +342,184 | Add 675.68% | 392,827 | $31.31 |
| Q1 2024 | +383,873 | Add 97.72% | 776,700 | $18.49 |
| Q2 2024 | +2.93 M | Add 377.68% | 3.71 M | $16.25 |
| Q3 2024 | -3.71 M | Sold Out | 3.71 M | $0.00 |
| Q4 2024 | +2.23 M | New Buy | 2.23 M | $18.35 |
| Q1 2025 | +2.42 M | Add 108.35% | 4.65 M | $16.61 |
| Q2 2025 | -1.48 M | Reduce 31.74% | 3.17 M | $21.57 |
| Q3 2025 | -1.69 M | Reduce 53.15% | 1.49 M | $21.34 |
Steven Cohen's ACADIA Pharmaceuticals Investment FAQs
Steven Cohen first purchased ACADIA Pharmaceuticals Inc. (ACAD) in Q2 2014, acquiring 1,082,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held ACADIA Pharmaceuticals Inc. (ACAD) for 46 quarters since Q2 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's largest addition to ACADIA Pharmaceuticals Inc. (ACAD) was in Q2 2024, adding 3,710,140 shares worth $60.29 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,486,357 shares of ACADIA Pharmaceuticals Inc. (ACAD), valued at approximately $31.72 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ACADIA Pharmaceuticals Inc. (ACAD) represents approximately 0.05% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's peak holding in ACADIA Pharmaceuticals Inc. (ACAD) was 4,647,816 shares, as reported at the end of Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.